Overview

An Assessment of Efficacy, Safety, and Pharmacokinetics of NBI-1117568 in Adults With Bipolar I Disorder With Current Mania

Status:
NOT_YET_RECRUITING
Trial end date:
2028-02-01
Target enrollment:
Participant gender:
Summary
The primary objective for this study is to evaluate the efficacy of NBI-1117568 compared with placebo on improving manic symptoms in adults with bipolar I disorder who are currently experiencing an episode of mania with or without mixed features.
Phase:
PHASE2
Details
Lead Sponsor:
Neurocrine Biosciences